Form 4: ClearPoint Neuro Director Acquires Stock as Compensation

ClearPoint Neuro Director Pascal Girin acquired 315 shares of common stock at $21.79 per share as part of his compensation plan.

Summary

• Pascal E. R. Girin, a Director of ClearPoint Neuro, Inc. (CLPT), acquired 315 shares of the company's common stock.
• The transaction occurred on October 1, 2025, with shares priced at $21.79 each.
• These shares were issued as payment for fees owed to Mr. Girin under the company's Non-Employee Director Compensation Plan.
• The issuance was made pursuant to the issuer's Sixth Amended and Restated 2013 Incentive Compensation Plan.
• The acquisition price of $21.79 per share was based on the closing price of the common stock on September 30, 2025.
• Following this transaction, Mr. Girin beneficially owns a total of 96,949 shares of ClearPoint Neuro common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transaction size is small, it signifies a director's continued equity stake and alignment with shareholder interests through stock-based compensation, which is generally viewed favorably.

Positives

• The acquisition of shares by a director aligns management's interests with those of shareholders, as their compensation is tied to the company's equity performance.
• Issuing stock as compensation is a common practice that can conserve cash for operational or strategic investments.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Stock-based compensation for non-employee directors is a standard practice across many industries, particularly in the medical technology and biotechnology sectors, to attract and retain qualified board members and align their incentives with long-term shareholder value.

Comparison to Industry Standards

• The use of equity as compensation for non-employee directors is a widely accepted corporate governance practice, consistent with benchmarks in the medical technology industry and broader public markets.
• Many companies, including peers in the medical device and neuro-tech space, utilize similar incentive compensation plans to remunerate directors and executives, fostering alignment with company performance.

Corporate Governance

Related Party Transactions

• Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., received 315 shares of common stock as payment for fees owed under the company's Non-Employee Director Compensation Plan.

Stakeholder Impact

• Shareholders may perceive this transaction as a positive indicator of director commitment and confidence in the company's future, as a portion of director compensation is directly tied to equity performance.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Insider Transaction, Form 4, Director Compensation, Equity Compensation, Stock Acquisition, Pascal Girin